A trusted advisor – Transforming patients’ lives with pioneering molecular diagnostics.
A prognostic and predictive test to guide ER+, HER2-, N0 and N+ breast cancer treatment decisions
The latest advance in
hereditary Cancer testing
The most comprehensive
HRD tumor test to guide
PARP inhibitor treatment
Management Message
Raymond Francot, Executive Vice President, International Operations
Myriad Genetics is the pioneer and worldwide leader in molecular diagnostics, offering innovative products that transform patients’ lives. Our products include tests for hereditary cancer, urological and breast cancer prognosis, carrier screening, melanoma diagnosis, depression, and autoimmune disorders. Myriad has partnered with several leading pharmaceutical companies to provide companion diagnostics to identify patients who can benefit from new cancer therapies.
Our Mission
Our Products
Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.
Our Pipeline
Myriad possesses the deepest diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need such as autoimmune diseases, dermatology, neuroscience, oncology, urology and women’s health. Myriad’s research investment totals $358 million over the past five years.
The Science
At Myriad, we use state-of-the art technologies including DNA sequencing, RNA analysis and proteomics to innovate and create the next generation of breakthrough diagnostics.
Our talented scientists are working in collaboration with universities, biotech and pharmaceutical companies, and government agencies to accelerate the pace of innovation for patients worldwide. This approach affords us a diversity of perspectives as well as access to cutting-edge science regardless of where it resides.
Who We Are
31st European Congress of Pathology (ECP)
Myriad is looking forward to meeting you at
the 31st European Congress of Pathology (ECP)
Nice . September 7-11, 2019
Please visit us at booth # R21
and learn more about EndoPredict
44th European Society for Medical Oncology (ESMO)
Myriad is looking forward to meeting you at
44th European Society for Medical Oncology (ESMO)
Barcelona . September 27 – October 1, 2019
PPlease come and visit Myriad’s booth
and learn more about EndoPredict
News Center
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
November 16, 2020Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China SALT LAKE CIT ...
German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
October 16, 2020German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Canc ...
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
August 21, 2020SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecula ...
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction
July 7, 2020Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Wo ...
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment
June 25, 2020SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagn ...
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer
June 4, 2020EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEW ...
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients
May 29, 2020SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular di ...
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
May 20, 2020SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagno ...
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
May 11, 2020SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagno ...
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
April 6, 2020More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) — ...
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
March 30, 2020SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diag ...
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer
March 18, 2020Prolaris One of Only Two Prognostic Tests Recommended for Expanded Indications SALT LAKE CITY, March 18, 2020 (GLOBE NEW ...
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy
February 14, 2020New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Mu ...
Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer
February 11, 2020Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Ca ...
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer
January 22, 2020Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer ...
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer
January 21, 2020Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-re ...
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
January 6, 2020New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospect ...
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
December 30, 2019Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patient ...
Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes
December 14, 2019Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Import ...
Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening
December 4, 2019Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive P ...
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
December 3, 2019Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium SA ...
The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis
November 20, 2019The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Meas ...
Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening
November 11, 2019New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Mu ...
New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis
November 9, 2019New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis ...
Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting
November 1, 2019Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting SA ...
Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting
October 28, 2019Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT ...
Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting
October 8, 2019Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting SALT LAKE ...
Myriad Announces Research Collaboration with University of Leeds
September 16, 2019Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prola ...
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment
September 5, 2019Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remai ...
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention
August 22, 2019Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More ...
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
August 7, 2019Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men ...
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer
June 27, 2019Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validati ...
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer
June 24, 2019BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Ly ...
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
June 3, 2019Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at Am ...
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
June 2, 2019BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Tr ...
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy
May 9, 2019New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forg ...
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer
April 30, 2019EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Can ...
Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test
April 9, 2019Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD ...
Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership
April 4, 2019Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership BRACAnalysis CDx® Test Will Be Used to Identify G ...
Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib
February 26, 2019Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted fro ...
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer
December 19, 2018BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® ...
EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer
December 19, 2018EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer NICE Decision is a Major ...
Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer
December 7, 2018Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer S ...
Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium
December 7, 2018EndoPredict is the Only Test to Answer Three Critical Questions: Risk of Breast Cancer Recurrence, Benefits of Chemother ...